The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

New discoveries in atherosclerosis pathways have shed light on the active mechanisms in other diseases such as chronic kidney disease (CKD) and HIV, paving the way for furture therapeutics.

The FINEARTS-HF study included 46% women, showing finerenone's efficacy in reducing cardiovascular events in HFmrEF/HFpEF ...

Posters presented at the American Heart Association Scientific Sessions included results that show how persistent disparities ...

Education and feedback for VHA pharmacists improved HF medication visits and prescribing, but personalized feedback did not ...

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center ...

Robert F. Kennedy Jr, a prominent antivaccine activist and former independent presidential candidate, has been nominated to ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

The connection between brain, mental, and cardiovascular health needs considerable more attention, argues Maureen Hood, PhD, RN, Uniformed Services University.

A decision from the American Board of Medical Specialties will be made about a new cardiovascular board by this upcoming February.